作者
Shubhadeep Sinha, Sreenivasa Chary, Pankaj Thakur, Leela Talluri, Mohan Reddy, Kamal K Verma, Pradeep Saha, Vijaya B Gupta, Kaja A Ramaiah, Siquafa Z Khanum, Leela Talluri Sr, Vijaya Gupta, Kaja Ramaiah, Siquafa Khanum
发表日期
2021/7/28
期刊
Cureus
卷号
13
期号
7
出版商
Cureus
简介
Background
Depression is a leading cause of psychiatric morbidity in the modern world, and the introduction of selective serotonin reuptake inhibitors (SSRIs) is a revolution in the treatment of depression. Vilazodone, a novel SSRI and 5-HT1A partial agonist, received FDA approval in 2011 to treat the major depressive disorder (MDD) in adults. This study conducted in India aimed to evaluate the efficacy and safety of vilazodone when compared to escitalopram or placebo in patients with MDD.
学术搜索中的文章
S Sinha, S Chary, P Thakur, L Talluri, M Reddy… - Cureus, 2021